Episode 113: Access to Optimal Care: Disparities Between EU and US
To shed light on the differences in oncologic care between the US and the EU, Chadi invites a returning guest as well as a newcomer: Jarushka Naidoo, MBBCH, MD, Chair of the Thoracic Oncology Division, Beaumont RCSI Cancer Centre (Dublin, Ireland), and Marina Chiara Garassino, MD, Professor of Medi…
Navigating the complexities of the NSCLC treatment pathway: A focus on antibody-drug conjugates
touchPANEL DISCUSSION for touchONCOLOGY
Listen to a panel of leading experts discuss the emerging role of antibody-drug conjugates (ADCs) in the treatment of patients with non-small cell lung cancer (NSCLC), including the mechanistic rationale and role of biomarkers in patient selection, the lates…
Metastatic Non-Small Cell Lung Cancer (NSCLC) Algorithm w/ Targetable Mutations - Dr. Jarushka Naidoo
Discussing the management of Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) with targetable mutations using the algorithm – with Dr. Jarushka Naidoo, Professor at Royal College of Surgeons in Ireland, Adjunct Professor at Department of Oncology - Sidney Kimmel Cancer Center at The Johns Hop…
BTOG Does...BRAF with Dr Tom Newsom-Davis and Professor Jarushka Naidoo
This episode features Dr Tom Newsom-Davis, BTOG Steering Committee Vice-Chair talking with Professor Jarushka Naidoo, Consultant Medical Oncologist at Beaumont Hospital, Dublin and Professor, RCSI.
ESMO 2023 Highlights: Early Stage NSCLC, SCLC, Thymic Carcinoma
Part 2 of our podcast coverage on ESMO 2023 includes an in-depth interview with Dr. Jarushka Naidoo on early-stage NSCLC, including updates from CheckMate816, Keynote 671 overall survival results, and Checkmate77T, first perceptions about the data, remaining unanswered questions and how to incorpor…
Navigating the clinical impact of TROP2-targeting in NSCLC
touchSYMPOSIUM for touchRESPIRATORY
Listen to this touchSYMPOSIUM recorded live in March 2025 at the The European Lung Cancer Congress in Paris, France.
Symposium chair Prof. Marina Garassino is joined by Prof. Jarushka Naidoo and Prof. David Planchard to explore the evolving role of TROP2-target…
Navigating the clinical impact of TROP2-targeting in NSCLC
touchSYMPOSIUM for touchONCOLOGY
Listen to this touchSYMPOSIUM recorded live in March 2025 at the The European Lung Cancer Congress in Paris, France.
Symposium chair Prof. Marina Garassino is joined by Prof. Jarushka Naidoo and Prof. David Planchard to explore the evolving role of TROP2-targeted…
ASCO 2022: Updates in Lung Cancer
The American Society of Clinical Oncology Annual Meeting 2022 brought together thousands of experts in oncology to hear new data and discuss how to improve the diagnosis and treatment of patients with cancer.
In this podcast, we hear from some of the leading experts in lung cancer, as they discuss…
Lung Cancer Considered -- Immunotherapy Toxicity: Myths & Pearls
Since the first immunotherapy agent for lung cancer was approved in 2015, this class of drugs has captured the imagination and the narrative for the treatment of driver negative lung cancer. Immunotherapy is now the standard of care for most patients with lung cancer in some form. And while not all…
موتور جستجوی پادکست
می توانید از وب سایت ما برای جستجوی پادکست های3,825,382و قسمت های195,883,418بر اساس افراد، مکان ها یا موضوعات استفاده کنید.
If I have seen further than others, it is by listening to podcasts and standing upon the shoulders of
giants.
‐ Isaac "Llamacorn" Newton
ویرایش
از کمک شما برای بروز نگهداشتن پایگاهدادههای پادکست سپاسگزاریم
